α2,6-sialic Acid on the Platelet Membrane Surface is a Novel Biomarker and Therapeutic Target in Children with Primary Immune Thrombocytopenia.

IF 1.9 4区医学 Q3 INTEGRATIVE & COMPLEMENTARY MEDICINE Alternative therapies in health and medicine Pub Date : 2024-10-01

Jingxin Gong, Zhaoyang Liu, Wenjuan Wang, Cuimin Zhu, Chen Li

{"title":"α2,6-sialic Acid on the Platelet Membrane Surface is a Novel Biomarker and Therapeutic Target in Children with Primary Immune Thrombocytopenia.","authors":"Jingxin Gong, Zhaoyang Liu, Wenjuan Wang, Cuimin Zhu, Chen Li","doi":"","DOIUrl":null,"url":null,"abstract":"Objective: To analyze the expression of platelet membrane glycoprotein sialylation in primary immune thrombocytopenia and provide a reference for clinical diagnosis and treatment of the disease.Methods: 100 children with primary immune thrombocytopenia diagnosed and treated in the Children's Hospital of Yunhe District Central Hospital of Cangzhou City, Hebei Province from January 2020 to June 2022 were included in the study group. All children were treated with dexamethasone (DXMS) shock therapy; Another 20 healthy children who underwent routine physical examination at the same time were selected and included in the control group. The study measured the platelet membrane surface in plasma using flow cytometry in two groups: the comparative study group and the control group. The study measured the positive rates of α 2,3-sialic acid (α 2, 3-sa) and α 2,6-sialic acid (α 2, 6-sa) in both groups. The study also measured the positive rates of α 2,3-sialic acid (α 2, 3-sa) and α 2,6-sialic acid (α 2, 6-sa) before and after treatment in the comparative study group. At the same time, an enzyme-linked immunosorbent assay was used to determine the content of sialic acid and sialidase activity and content in the serum. The detection values of α2, 3-SA, and α2, 6-SA expression of children in the study group and the control group were compared, and the detection values of α2, 3-SA, and α2, 6-SA expression of children in the study group before and after treatment were compared.Results: There was no significant difference in the positive rate of α 2, 3-sa between the study group and the control group (t=0.852, P > .05); Study Group: The positive rate of α 2,6-sa was significantly lower than that of the control group (P < .05). In the study group, there was no significant difference in the positive rate of α 2,3-sa before and after treatment (P > .05). However, after treatment, the positive rate of α 2,6-sa was significantly higher than before (P < .05). The study found that the children in the study group had significantly higher levels of serum sialic acid content, sialidase activity, and content than those in the control group (P < .05). After treatment, the children in the study group showed a decrease in serum sialic acid content, sialidase activity, and content, which was statistically significant (P < .05) compared to before treatment.Conclusion: The sialylation of platelet membrane glycoprotein is abnormally expressed in primary immune thrombocytopenia. The sialylation of platelet membrane glycoprotein may be involved in the occurrence and development of the disease. It is of great practical significance to diagnose and evaluate the therapeutic effect of the disease by detecting the sialylation of platelet membrane glycoprotein.","PeriodicalId":7571,"journal":{"name":"Alternative therapies in health and medicine","volume":" ","pages":"533-537"},"PeriodicalIF":1.9000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alternative therapies in health and medicine","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To analyze the expression of platelet membrane glycoprotein sialylation in primary immune thrombocytopenia and provide a reference for clinical diagnosis and treatment of the disease.

Methods: 100 children with primary immune thrombocytopenia diagnosed and treated in the Children's Hospital of Yunhe District Central Hospital of Cangzhou City, Hebei Province from January 2020 to June 2022 were included in the study group. All children were treated with dexamethasone (DXMS) shock therapy; Another 20 healthy children who underwent routine physical examination at the same time were selected and included in the control group. The study measured the platelet membrane surface in plasma using flow cytometry in two groups: the comparative study group and the control group. The study measured the positive rates of α 2,3-sialic acid (α 2, 3-sa) and α 2,6-sialic acid (α 2, 6-sa) in both groups. The study also measured the positive rates of α 2,3-sialic acid (α 2, 3-sa) and α 2,6-sialic acid (α 2, 6-sa) before and after treatment in the comparative study group. At the same time, an enzyme-linked immunosorbent assay was used to determine the content of sialic acid and sialidase activity and content in the serum. The detection values of α2, 3-SA, and α2, 6-SA expression of children in the study group and the control group were compared, and the detection values of α2, 3-SA, and α2, 6-SA expression of children in the study group before and after treatment were compared.

Results: There was no significant difference in the positive rate of α 2, 3-sa between the study group and the control group (t=0.852, P > .05); Study Group: The positive rate of α 2,6-sa was significantly lower than that of the control group (P < .05). In the study group, there was no significant difference in the positive rate of α 2,3-sa before and after treatment (P > .05). However, after treatment, the positive rate of α 2,6-sa was significantly higher than before (P < .05). The study found that the children in the study group had significantly higher levels of serum sialic acid content, sialidase activity, and content than those in the control group (P < .05). After treatment, the children in the study group showed a decrease in serum sialic acid content, sialidase activity, and content, which was statistically significant (P < .05) compared to before treatment.

Conclusion: The sialylation of platelet membrane glycoprotein is abnormally expressed in primary immune thrombocytopenia. The sialylation of platelet membrane glycoprotein may be involved in the occurrence and development of the disease. It is of great practical significance to diagnose and evaluate the therapeutic effect of the disease by detecting the sialylation of platelet membrane glycoprotein.

微信好友朋友圈 QQ好友复制链接

本刊更多论文

血小板膜表面的α2,6-硫辛酸是原发性免疫性血小板减少症儿童的新型生物标记物和治疗靶点

目的方法：选取2020年1月-2022年6月在河北省沧州市云和区中心医院儿童医院诊治的100例原发性免疫性血小板减少症患儿为研究对象。所有患儿均接受地塞米松（DXMS）冲击治疗；另选取20名同时接受常规体检的健康儿童作为对照组。研究采用流式细胞术测量了两组血浆中血小板膜表面的情况：对比研究组和对照组。研究测量了两组中α 2，3-sialic acid（α 2，3-sa）和α 2，6-sialic acid（α 2，6-sa）的阳性率。研究还测量了对比研究组治疗前后α 2,3-sialic酸（α 2,3-sa）和α 2,6-sialic酸（α 2,6-sa）的阳性率。同时，采用酶联免疫吸附试验测定血清中的硅氨酸含量和硅氨酸酶活性及含量。比较研究组和对照组患儿α2、3-SA和α2、6-SA的检出值，并比较研究组患儿治疗前后α2、3-SA和α2、6-SA的检出值：研究组与对照组α2，3-SA阳性率差异无学意义（t=0.852，P>0.05）；研究组α2，3-SA阳性率与对照组差异无学意义（t=0.852，P>0.05）：研究组：α 2,6-sa 的阳性率明显低于对照组（P < .05）。在研究组中，α 2,3-sa 的阳性率在治疗前后无明显差异（P > .05）。但治疗后，α 2,6-sa 的阳性率明显高于治疗前（P < .05）。研究发现，研究组患儿的血清中唾液酸含量、唾液酸酶活性和含量均明显高于对照组患儿（P < .05）。治疗后，研究组儿童的血清中ialic酸含量、sialidase活性和含量均有所下降，与治疗前相比，差异有统计学意义（P < .05）：结论：原发性免疫性血小板减少症患者血小板膜糖蛋白的糖基化表达异常。结论：血小板膜糖蛋白的糖基化在原发性免疫性血小板减少症中表达异常，血小板膜糖蛋白的糖基化可能与该病的发生和发展有关。通过检测血小板膜糖蛋白的糖苷酰化对该病的诊断和疗效评估具有重要的现实意义。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Alternative therapies in health and medicine INTEGRATIVE & COMPLEMENTARY MEDICINE-

CiteScore

0.90

自引率

0.00%

发文量

219

期刊介绍： Launched in 1995, Alternative Therapies in Health and Medicine has a mission to promote the art and science of integrative medicine and a responsibility to improve public health. We strive to maintain the highest standards of ethical medical journalism independent of special interests that is timely, accurate, and a pleasure to read. We publish original, peer-reviewed scientific articles that provide health care providers with continuing education to promote health, prevent illness, and treat disease. Alternative Therapies in Health and Medicine was the first journal in this field to be indexed in the National Library of Medicine. In 2006, 2007, and 2008, ATHM had the highest impact factor ranking of any independently published peer-reviewed CAM journal in the United States—meaning that its research articles were cited more frequently than any other journal’s in the field. Alternative Therapies in Health and Medicine does not endorse any particular system or method but promotes the evaluation and appropriate use of all effective therapeutic approaches. Each issue contains a variety of disciplined inquiry methods, from case reports to original scientific research to systematic reviews. The editors encourage the integration of evidence-based emerging therapies with conventional medical practices by licensed health care providers in a way that promotes a comprehensive approach to health care that is focused on wellness, prevention, and healing. Alternative Therapies in Health and Medicine hopes to inform all licensed health care practitioners about developments in fields other than their own and to foster an ongoing debate about the scientific, clinical, historical, legal, political, and cultural issues that affect all of health care.